Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
January 6, 2026European Journal of Heart FailureOpen Access

EJHF expert consensus statement on the diagnosis and management of hypertrophic cardiomyopathy

View Full Paper
Ask AI
Bookmark
Share

Why the study?

While aligned with current ESC and AHA/ACC guidelines, clinicians require further guidance in key areas and current controversies regarding the diagnosis and management of hypertrophic cardiomyopathy.

Design

Expert consensus statement

Authors

BMBenjamin MederLLLeslie A. LeinwandMPMaurizio Pieroni

Discussion

Loading...

Member takes

Overview

Offers clinicians updated HCM pathways beyond 2023-2024 guidelines; extends consensus by addressing controversies and research gaps.

Structured PICO

P
Population
Patients with hypertrophic cardiomyopathy (HCM), including young and older adults, pregnant women, paediatric patients, and genotype-positive/phenotype-negative individuals.
I
Intervention
Diagnostic and management strategies including multimodal imaging, genetic testing, risk stratification, pharmacologic treatment (beta-blockers, calcium channel blockers, disopyramide, cardiac myosin inhibitors such as mavacamten and aficamten), and septal reduction therapies.

This consensus statement provides comprehensive, multidisciplinary guidance on the diagnosis and management of hypertrophic cardiomyopathy, addressing current controversies and future directions.

Cite This Study

Meder et al. (2026) studied this question.

synapsesocial.com/papers/6a7d84af7bc3bc4145999d58https://doi.org/10.1093/ejhf/xuaf008
View Full Paper
Ask AI
Bookmark
Share